NVCR
$12.35
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, an...
Recent News
Novocure's Optune Lua Gets Japan Reimbursement for NSCLC Treatment
NVCR gains Japan NHI reimbursement for Optune Lua in advanced NSCLC, expanding patient access and supporting adoption of its TTFields cancer therapy platform.
NovoCure (NVCR) Reliance on International Sales: What Investors Need to Know
Explore NovoCure's (NVCR) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
A Look At NovoCure (NVCR) Valuation As Record 2025 Results And Optune Pax Approval Reset Growth Expectations
NovoCure (NVCR) just packed several key developments into one week, reporting record 2025 revenue of US$655.35 million, topping fourth quarter expectations, issuing 2026 guidance, and launching FDA approved Optune Pax for locally advanced pancreatic cancer. See our latest analysis for NovoCure. At a share price of US$13.67, NovoCure’s recent momentum has tilted positive, with a 7 day share price return of 20.33% and a 90 day share price return of 17.04%. This comes even as the 1 year total...
NovoCure Limited Q4 2025 Earnings Call Summary
Moby summary of NovoCure Limited's Q4 2025 earnings call
NovoCure Ltd (NVCR) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic Growth Plans ...
NovoCure Ltd (NVCR) reports an 8% revenue increase for 2025, outlines growth strategies, and addresses operational challenges in its latest earnings call.